Back to speakers

Seng Gee LIM


City: Singapore

Institution: National University Health System

Biography of Seng Gee LIM

Professor Seng Gee Lim, FRACP, FRCP, FAMS, MD, is Director of Hepatology at the Division of Gastroenterology and Hepatology, National University Health System, Singapore, and was previously Chief of Division.

He graduated in 1980 from Monash Medical School completed his research MD at the Royal Free Hospital.

He is a member of the editorial boards for Liver International, Journal of Viral Hepatitis, Hepatology International, Alimentary Pharmacology and Therapeutics, Lancet Gastroenterology & Hepatology, and Evidence Based Internal Medicine Solutions, He is also on the advisory board of Gilead
Sciences, Novartis Pharmaceuticals, Bristol Myers Pharmaceuticals, Merck Sharpe and Dohme Pharmaceuticals, Springbank, Abbvie and Abbott Diagnostics.

He is currently chairman of the Singapore Hepatology Conference and Science of HBV cure conference, and was previously the Chairman of the Asia Pacific
Association for Study of the Liver (APASL) Liver Week 2013 Congress. He served as Governing Council member from 2014-2018 of the International Association for Study of Liver (IASL), and has been appointed to the AASLD Asia Pacific Regional Advisory Council in 2018. He is faculty at the Asia
Pacific EBM workshop. His research includes clinical trials of new treatments for chronic hepatitis B and C, and translational research in viral hepatitis, involving molecular biology and immunology of hepatitis B. He has over 207 peer review publications and has been awarded over $36 million in grant funding for his research, including a recent award of a $25 million National Translational Clinical Research grant in 2015 to investigate eradication of HBV. In 2018 he was awarded the NMRC Clinician Scientist Award for research in HBV.

PHC's participations

Monday, March 27th 2023

Long term effects of NUCs -

Monday, March 08th 2021

HEPATITIS B (chairman)

Is elimination of HBV realistic ?

13th PHC – 2020

Monday, January 13th 2020

HEPATITIS B - SESSION 1: therapy of hepatitis B today: HBV suppression (chairman) -

Who to treat? A critical review of the international guidelines -

Tuesday, January 14th 2020

LUNCH WORKSHOPS - 1. Treatment of hepatitis B: the guidelines and real life: Room 242B (chairman)

12th PHC – 2019

Tuesday, January 15th 2019

HEPATITIS B - SESSION 1 (chairman)

Treatment during pregnancy -

6th PHC – 2013

Tuesday, January 15th 2013

Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)

7th PHC – 2014

Tuesday, January 14th 2014

Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)

10th PHC – 2017

Tuesday, January 31st 2017

When can we stop NUCS in patients with chronic hepatitis B? -